National Institutes of Health

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Endomimetics is focused on developing advanced bio-nanometric coating technology aimed at enhancing medical care for patients with kidney diseases. The company's innovative stent coating technology is designed to closely mimic human tissue, which helps to minimize the need for additional surgeries and improves the longevity of the devices. By reducing complications associated with the implantation of foreign materials, Endomimetics' technology aims to provide better outcomes for patients, ultimately improving their overall quality of care in the management of kidney-related health issues.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Matregenix is a MedTech company based in Irvine, California, founded in 2018 by Sherif Soliman. The company specializes in the development and manufacturing of advanced nanofibrous materials tailored for various medical applications. Its flagship product, MatriNova, is a barrier membrane designed for periodontal surgeries, featuring customizable characteristics that enhance its performance. Utilizing electrospinning technology, Matregenix produces materials with predictable resorption times and improved handling properties. In addition to its focus on the biomedical sector, the company also offers comprehensive contract development and manufacturing services aimed at assisting manufacturers in bringing innovative products to market.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Nanoscope Therapeutics Inc. specializes in developing innovative gene therapies aimed at restoring vision for individuals suffering from retinal degenerative diseases, including retinitis pigmentosa and dry age-related macular degeneration. Founded in 2017 and based in Bedford, Texas, the company employs light-sensitive molecules and light-assisted gene delivery techniques to target and treat specific areas of the retina. This approach allows for the re-sensitization of retinal cells to low light levels, enabling patients to regain some degree of vision. Nanoscope's therapeutic platform focuses on providing effective solutions for vision loss, addressing a significant unmet need in the field of ocular health.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Ceres Nanosciences, Inc., established in 2008 and based in Manassas, Virginia, specializes in the research, development, and commercialization of innovative sample preparation products and diagnostic tests. The company's core technology, Nanotrap, captures, enriches, and preserves biomarkers from various biofluid matrices, facilitating early detection of diseases such as cancer, cardiac, and infectious diseases. Ceres' lead product is a direct antigen test for Lyme disease diagnosis, slated for commercial release in 2015. The company's product pipeline includes advanced sample collection technologies and diagnostics, funded through federal grants and industry collaborations.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Ceres Nanosciences, Inc., established in 2008 and based in Manassas, Virginia, specializes in the research, development, and commercialization of innovative sample preparation products and diagnostic tests. The company's core technology, Nanotrap, captures, enriches, and preserves biomarkers from various biofluid matrices, facilitating early detection of diseases such as cancer, cardiac, and infectious diseases. Ceres' lead product is a direct antigen test for Lyme disease diagnosis, slated for commercial release in 2015. The company's product pipeline includes advanced sample collection technologies and diagnostics, funded through federal grants and industry collaborations.

NanoScope Technologies, founded in 2009, focuses on developing innovative methods and devices for scientific, industrial, and biomedical applications. The company specializes in a range of biomedical technologies, including diagnostics and therapeutic devices, as well as molecules that facilitate advanced medical research. Their offerings support optical gene delivery, functional imaging, neuromodulation, and optical manipulation. By providing access to next-generation biomedical stimulation and imaging platforms, NanoScope enables medical researchers to enhance diagnostic outcomes and improve patient care. The technologies developed by the company have attracted interest from various clinicians and industry leaders, highlighting their potential for real-world application.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Ceres Nanosciences, Inc., established in 2008 and based in Manassas, Virginia, specializes in the research, development, and commercialization of innovative sample preparation products and diagnostic tests. The company's core technology, Nanotrap, captures, enriches, and preserves biomarkers from various biofluid matrices, facilitating early detection of diseases such as cancer, cardiac, and infectious diseases. Ceres' lead product is a direct antigen test for Lyme disease diagnosis, slated for commercial release in 2015. The company's product pipeline includes advanced sample collection technologies and diagnostics, funded through federal grants and industry collaborations.

POP Biotechnologies is a life sciences company based in Buffalo, NY, focused on enhancing individual health through innovative nanomedicine solutions. The company develops targeted therapies aimed at treating cancer and other serious diseases, utilizing advanced nanoparticle-based drug delivery systems. Their proprietary technology allows for the precise release of drug payloads when activated by near-infrared light, providing healthcare providers with effective tools to address patient needs in oncology and infectious diseases.

The Cornell High Energy Synchrotron Source is a science and technology laboratory. They assist in the development of equipment that supports research and experiments. They will make undulator beamtime available for certain user groups to create new tools, processes, and synchrotron radiation applications. They provide resources for physics, chemistry, biology, environmental science, and materials science research.

Viewpoint Molecular Targeting develops radiopharmaceutical therapeutics for cancer and complementary diagnostic imaging agents that enable a personalized approach to cancer therapy. ViewpointMT's alpha-particle radiotherapies deliver alpha radiation specifically to cancer cells utilizing specialized targeting peptides. ViewpointMT is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Versatope Therapeutics is a preclinical-stage biotechnology company specializing in immunotherapy. The company has developed a unique bacterial factory nanoparticle technology that allows for the display of multiple epitopes, addressing the challenges of strain-specific immunity. This innovative approach aims to enhance vaccine potency and improve therapeutic delivery. By enabling the creation of a single vaccine capable of protecting against multiple strains of influenza, Versatope seeks to provide solutions that can significantly advance vaccine development for biotechnology companies.

NanoScope Technologies, founded in 2009, focuses on developing innovative methods and devices for scientific, industrial, and biomedical applications. The company specializes in a range of biomedical technologies, including diagnostics and therapeutic devices, as well as molecules that facilitate advanced medical research. Their offerings support optical gene delivery, functional imaging, neuromodulation, and optical manipulation. By providing access to next-generation biomedical stimulation and imaging platforms, NanoScope enables medical researchers to enhance diagnostic outcomes and improve patient care. The technologies developed by the company have attracted interest from various clinicians and industry leaders, highlighting their potential for real-world application.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.